1 / 12

Digital Pathology in the Era of Global Clinical Trials: Improving Quality and Consistency

Digital Pathology in the Era of Global Clinical Trials: Improving Quality and Consistency. Ron Luff, MD, MPH. Global Reach. UK. Belgium. USA. China. India. Singapore. Australia. Quest Diagnostics Clinical Trials Laboratories & Offices. Affiliate Laboratories.

alodie
Download Presentation

Digital Pathology in the Era of Global Clinical Trials: Improving Quality and Consistency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Digital Pathology in the Era of Global Clinical Trials:Improving Quality and Consistency Ron Luff, MD, MPH

  2. Global Reach UK Belgium USA China India Singapore Australia Quest Diagnostics Clinical Trials Laboratories & Offices Affiliate Laboratories

  3. Proprietary Facilities:US, UK, and India • Two facilities in Los Angeles (Lab and Project Mgmt), plus a lab in San Juan Capistrano, CA (Nichols Institute), a lab in Teterboro, NJ and an administrative facility in Collegeville, PA • >300 US employees • Service Areas include: • North America • Central America • South America • Australia • South East Asia • Two facilities near London (Heston – Lab; Hounslow – Proj. Mgmt), plus Project Mgmt in Wavre, Belgium • ~300 EU employees • Multiple language expertise • Services Areas include: • Europe • Middle East • Africa • India • New 65,000 sq.ft. laboratory in Gurgaon, India (New Delhi); supporting local investigators / trials and global clinical trials • Service Areas include: • India • Pacific Region

  4. Core Competencies by Therapy

  5. Cellular Pathology, circa 1858-present • Light microscopy “art-form” • Variation of diagnoses among • “experts” • “Truth” often determined by • majority rule in adjudication • for clinical trials cases

  6. Digital Pathology San Juan Capistrano, CA Chantilly, VA NAS NAS WAN 5tb CIFS Share 5 tb CIFS Share NS40 PSI NS40 PSI QDC CLARiiON 146 GB SQL/Server Meta Data Database Digital Cellular Pathology, circa 1996-present • Quest Diagnostics’ reference laboratory placed 4 scanners in 2007 (Nichols Institute) • Primary use • Remote viewing of reference IHC cases in a faster, yet equally accurate manner • Digital analysis when requested (eg, Ki67 quantitation)

  7. Digital Pathology for Clinical Trials,circa 1996-present • Reduce variation of diagnoses and allow for “remote” prospective reads by central pathologist(s) • Standardization among different labs

  8. Digital Pathology for Clinical TrialsAdditional Advantages • Long-term storage of images • “Digital” slide • No risk of breakage and stain fade • Enables use of tissue section for other purposes (eg, DNA studies) • Remote “anytime” access to digital slides • Enables trial sponsors to study slides • Conferencing capabilities • Multiple people can review slides simultaneously

  9. Digital Pathology for Clinical TrialsAdditional Advantages • Digitized slides can substitute for tissue/ cytology samples when global trial host country restricts exportation • Digital analysis can be used for • Quantifying stains • Microvessel density assessment • Rare event detection • Protein quantitation within cellular compartments when used in conjunction with immunofluorescence

  10. Epidermal Growth Factor Receptor (EGFR) • Part of a family of four related cell surface tyrosine kinase receptors • Often mutated and upregulated in epithelial cancers (NSSC of lung, head and neck squamous carcinoma, colon adenocarcinoma) • Overexpression predicts response to certain therapies (eg, gefitinib) • EGFR status determined by FISH or immunohistochemistry (IHC) staining – until recently, subjective interpretation

  11. IHC Staining for EGFR 20X 400X Strongly Positive ??Positive

  12. Digital Assessment • Digital computerized assessment of membrane receptor • 3+ Cells = 174 • 2+ Cells = 153 • 1+ Cells = 78 • 0+ Cells = 36 • Total Cells = 441 Analysis provided by Trevor Johnson, Aperio.

More Related